TLSA — Tiziana Life Sciences Share News
0.000.00%
Last trade - 00:00- $115.83m
- $113.58m
Brief: Tiziana Announces Reduction Of Side Effects Commonly Seen With Discontinuation Of GLP-1 Agonists With Nasal Anti-CD3
Brief: Tiziana Life Sciences Announces Registered Direct Offering Of About $10 Mln
Brief: Tiziana Life Sciences Announces Positive Results From Ozempic And Nasal Anti-CD3 Combination Study
Brief: Tiziana Life Sciences Awarded $4 Mln Grant By National Institutes Of Health
Brief: Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule
Brief: Tiziana Life Sciences Granted FDA Fast Track Designation
Brief: FDA Accepts Tiziana Life Sciences Fast Track Designation Submission For Treatment Of Multiple Sclerosis
Brief: Tiziana Life Sciences Applied For FDA Orphan Drug Designation Of Foralumab For na-SPMS
Brief: Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
Brief: Tiziana Life Sciences Files For Orphan Drug Designation For Intranasal Foralumab
Brief: Tiziana Life Sciences Announces Updated Clinical And Pet Scan Findings For Intranasal Foralumab
Brief: Tiziana Life Sciences Files New Patent Application for Combination Therapy of Anti-CD3 With GLP-1 Receptor Agonist
Brief: Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
Brief: Tiziana Life Sciences Announces Positive Six-Month Clinical Results In Multiple Sclerosis Patients Treated With Intranasal Foralumab
Brief: Tiziana Announces Positive Qualitative Six-Month Pet Scan Results
Brief: Tiziana Life Sciences Initiates Multi-Center Phase 2A Clinical Trial Of Intranasal Foralumab
Tiziana gains on FDA clearance to start Alzheimer's treatment study
Brief: Tiziana Life Sciences Announces FDA Ind Clearance Of Intranasal Foralumab For The Treatment Of Alzheimer’S Disease
Brief: Tiziana Life Sciences Receives Nasdaq Deficiency Notice